Merck

Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
Mon, 02/11/19 - 08:24 pm
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
FDA promises speedy review on moving Merck's Keytruda up as first-line head and neck cancer therapy
Endpoints
Mon, 02/11/19 - 10:24 am
Merck
Keytruda
FDA
head and neck cancer
priority review
Artificial Intelligence Gaining Ground in Drug Development
BioSpace
Mon, 02/11/19 - 10:00 am
CASP
machine learning
artificial intelligence
drug development
Merck
Takeda
Atomwise
Bayer
GSK
Google DeepMind
Recursion Pharmaceuticals
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Sun, 02/10/19 - 11:08 pm
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Fri, 02/8/19 - 11:40 am
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
CEOs of Pfizer, Merck, Sanofi to testify in Senate drug pricing hearing
Biopharma Dive
Wed, 02/6/19 - 01:27 pm
Pfizer
Sanofi
Merck
drug pricing
Senate
Powerful Senate committee invites pharma executives to testify
Reuters
Tue, 02/5/19 - 11:31 pm
Senate
drug pricing
AbbVie
AstraZeneca
Bristol-Myers Squibb
JNJ
Merck
Pfizer
Sanofi
4 Things You Need to Know About Merck's Q4 Earnings Results
Motley Fool
Sun, 02/3/19 - 12:48 pm
Merck
earnings
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
Sat, 02/2/19 - 12:31 pm
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Merck analysts to CEO: What’s so great about your pipeline beyond Keytruda?
Fierce Pharma
Fri, 02/1/19 - 12:15 pm
Merck
Keytruda
vaccines
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing
BioSpace
Fri, 02/1/19 - 11:27 am
earnings
Pfizer
Amgen
AbbVie
JNJ
Merck
Novo Nordisk
Takeda
Merck 4Q net powered by cancer treatment sales, lower taxes
Yahoo/AP
Fri, 02/1/19 - 09:59 am
Merck
earnings
FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game
Endpoints
Thu, 01/31/19 - 11:27 am
Merck
V114
vaccines
FDA
breakthrough status
Prevnar 13
Pfizer
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Forbes
Mon, 01/28/19 - 11:00 am
Big Pharma
Pfizer
Merck
AstraZeneca
Gilead Sciences
Alexion
Vertex Pharmaceuticals
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Yahoo/Motley Fool
Sun, 01/20/19 - 03:20 pm
drug pricing
Big Pharma
Amgen
AstraZeneca
Pfizer
GSK
Merck
Gilead
FDA Approves 17th Biosimilar, Third for Herceptin
RAPS.org
Fri, 01/18/19 - 09:44 pm
FDA
Merck
Samsung Bioepis
Ontruzant
biosimilars
Roche
Herceptin
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter
Xconomy
Wed, 01/16/19 - 10:07 am
Merck
Roger Perlmutter. immuno-oncology
Merck's Keytruda slashes death risk by 31% in esophageal cancer victory
Fierce Pharma
Tue, 01/15/19 - 12:02 am
Merck
Keytruda
esophageal cancer
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly

Pages